NCT07474961Not yet recruitingPhase 4
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
A Multicentre, Adaptive, Randomised, Multidomain, Platform Trial for Dose Optimization in the Treatment of Adult Patients With Haematological Diseases (BLOOD-dose): Core Protocol
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases. The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions. New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 4 Mar 2026
- Start date
- Mar 2027
- Primary completion date
- Dec 2036
- Lead sponsor
- Anne Louise Tølbøll Sørensen
- Diseases
- Multiple myeloma
- NCT number
- NCT07474961
- EU CT number
- 2026-525658-13-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 400
- From Mar 2027 to the primary completion date, Dec 2036
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that, in the opinion of the investigator, impairs the participant's ability to understand trial procedures, provide informed consent and/or interfere with participation and/or compliance in the trial.
- Domain eligibility criteria: each domain has its own specific eligibility criteria detailed in each DSA.
Other
- The participant tient is expected to live less than 3 months, as judged by the investigator.
Who the study is looking for
- Participants of any sex who are at least 18 years of age at the time of providing informed consent.
- Participant diagnosed with a haematological disease, i.e. any disorder that primarily affects the blood, bone marrow, the lymphatic system and/or blood-forming organs.
- Should be eligible for participation in at least one of the currently active domains.
- Capable of giving signed informed consent for each applicable DSA(s). By consenting to a domain, participants also consent to participation in BLOOD-dose.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg University Hospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Unknown status |
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Unknown status |
| Copenhagen University Hospital, Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
| Odense University Hospital Coordinator of this site? Confirm its status | Odense | Denmark | Unknown status |
| Roskilde University Hospital Coordinator of this site? Confirm its status | Roskilde | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.